Three 'Male Menopause' Stocks With Muscle

Repros was up 7 cents to $11.36 in recent trading.

Auxillium Pharmaceuticals(AUXL Quote - Cramer on AUXL - Stock Picks):

Auxillium has performed very well with Testim, a once-daily testosterone gel that is grabbing steady market share from market leader Androgel, sold by Solvay. Auxillium has benefited from clinical data that shows Testim delivers more testosterone than Androgel.

Since launching in 2003, Testim sales have racked up a compound annual growth rate of almost 75%. As of August, Testim's share of the testosterone gel market was 20.5% and growing. Sales in the first half of 2007 totaled $42 million, which puts the company on track to meet its projected sales guidance of $88 million to $92 million for the year.

While Auxillim should continue to increase Testim's market share, just as importantly, the product creates a solid base business that the company can use to invest in other pipeline drugs. Most notable is Xiaflex, an enzyme that breaks down collagen and is being developed to treat three different diseases in which collagen builds up abnormally to create painful and movement-restricting nodules under the skin.

Auxillium was up 3 cents to $23.52.

« Previous Page

1 2 3 4

Next Page »